The invention provides a polypeptide that is not full length Anthrax Lethal Factor (LF) or a fusion thereof, comprising or consisting of one or more sequences selected from the group of LF457-486, LF467-486, LF101-120, LF171-190, LF241-260, LF251-270, LF261-280, LF281-300, LF457-476, LF467-486, LF547-567, LF574-593, LF584-603, LF594-613, LF604-623, LF644-663, LF674-693, LF694-713 and LF714-733, and further provides a polynucleotide encoding such a polypeptide or a vector comprising such a polynucleotide, optionally wherein the vector is an adenoviral vector. A method for vaccinating a subject against anthrax or B. anthracis comprising the step of exposing the subject to a polypeptide, polynucleotide, vector, host cell or composition of the invention, optionally wherein the subject is a human or a livestock or domestic animal.
